AI Analysis
AI-generated analysis. Always verify with the original filing.
Adagene announced a clinical collaboration with Incyte to evaluate muzastotug in combination with INCA33890 in MSS CRC patients and reported updated Phase 1b/2 data showing improved efficacy and safety for muzastotug combined with pembrolizumab.
Key Takeaways
1Adagene entered a clinical collaboration with Incyte to evaluate muzastotug (ADG126) combined with INCA33890 in MSS CRC patients, with Incyte sponsoring the study and Adagene supplying muzastotug.
2Updated Phase 1b/2 data showed muzastotug with pembrolizumab achieved a 31% ORR at 20 mg/kg versus 13% at 10 mg/kg in MSS CRC patients without liver metastases.
3Median PFS was 6.7 months at 20 mg/kg versus 4.8 months at 10 mg/kg, with median OS not yet reached at 20 mg/kg and 19.8 months at 10 mg/kg.
4Safety data showed no Grade 4/5 TRAEs, a 4% discontinuation rate, and manageable Grade 3 TRAEs of 15% at 10 mg/kg and 38% at 20 mg/kg.
5A randomized Phase 2 trial is ongoing with results expected in 1H 2027, and muzastotug has FDA Fast Track designation for MSS mCRC without liver metastases.